Dr. Reddy’s Laboratories secured European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, for osteoporosis and bone complications. This significant milestone, following a positive CHMP recommendation, allows marketing across EU member states and EEA countries. Dr. Reddy’s, in partnership with Alvotech, will commercialize the drug under brands Acyvbra and Xbonzy.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets